Using raloxifene to treat neurodegenerative diseases like ALS
Raloxifene-Based Therapy in Neuro Degenerative Diseases
This study is looking at whether raloxifene, a medicine usually used for bone health, can help people with ALS by improving brain cell function and slowing down the disease, while also checking if there are differences in how the disease affects men and women.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10991395 on NIH RePORTER |
What this research studies
This research investigates how raloxifene, a medication typically used for osteoporosis, may help treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The study focuses on understanding the role of mitochondrial dysfunction and the ubiquitin-proteasome pathway in the central nervous system, particularly how these factors contribute to disease progression. Researchers are exploring the differences in disease onset between males and females and how activating certain cellular pathways could potentially delay the progression of ALS. Patients may be treated with raloxifene to see if it can improve proteasome activity and overall cellular health in the brain.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with amyotrophic lateral sclerosis or related neurodegenerative conditions.
Not a fit: Patients with neurodegenerative diseases not related to ALS or those who do not respond to hormonal therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that slow the progression of ALS and other neurodegenerative diseases.
How similar studies have performed: Previous research has shown promise in using hormonal therapies for neurodegenerative diseases, but this specific approach with raloxifene is relatively novel.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Germain, Doris a — Icahn School of Medicine at Mount Sinai
- Study coordinator: Germain, Doris a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.